多索茶碱与布地奈德联合治疗支气管哮喘急性发作疗效观察
|
摘要
目的分析多索茶碱与布地奈德联合治疗急性发作的支气管哮喘效果。方法选取支气管哮喘急性发作患者134例,随机分为两组,各67例。对照组给予布地奈德吸入,2吸(200μg)/次,2次/d;在此基础上,观察组给予多索茶碱片口服,200μg(1片)/次,2次/d。观察比较两组治疗前后FEV1、FVC、FEV1/FVC及IL-23、总有效率及不良反应发生情况。结果观察组总有效率为94.0%,显著高于对照组的82.1%(P<0.05),而口干、恶心、呕吐、面红等总发生率为10.4%,与对照组的7.5%比较,差异无统计学意义。治疗前两组FEV1/FVC等指标及血清IL-23水平比较,差异无统计学意义;治疗后两组均显著改善,且观察组改善幅度较大,组间比较差异有统计学意义(P<0.05)。结论对于支气管哮喘急性发作患者,多索茶碱与布地奈德联合有着显著效果,且口干、恶心、呕吐、面红等发生率增加不明显,值得推广。
Objective To observe the clinical efficacy of doxofylline combined with budesonide on the treatment of bronchial asthma.Methods134 patients with bronchial asthma were randomly distributed into two groups.Control group(67 patients) was treated withbudesonide,and observation group(67 patients) was treated with doxofylline on the base of controlgroup.The treated time of two groups was 14 days.The total effective rate,changes of lung function and IL-23,and incidences of adverse effect were observed.Results The total effective rate of observation group was94.0%,and control group was 82.1%.There was a significant difference between the groups.The pulmonary function and IL-23 after treatment in observation group was more relieved than that of controlgroup after treatment.The incidences of adverse effect in observation group was 10.4%,and control group was 7.5%.There was no significant difference between the groups.Conclusion The treatment of doxofylline combined with budesonide on the treatment of bronchial asthma had a good effect and more safety,and worthy to be popularized.
Objective To observe the clinical efficacy of doxofylline combined with budesonide on the treatment of bronchial asthma.Methods134 patients with bronchial asthma were randomly distributed into two groups.Control group(67 patients) was treated withbudesonide,and observation group(67 patients) was treated with doxofylline on the base of controlgroup.The treated time of two groups was 14 days.The total effective rate,changes of lung function and IL-23,and incidences of adverse effect were observed.Results The total effective rate of observation group was94.0%,and control group was 82.1%.There was a significant difference between the groups.The pulmonary function and IL-23 after treatment in observation group was more relieved than that of controlgroup after treatment.The incidences of adverse effect in observation group was 10.4%,and control group was 7.5%.There was no significant difference between the groups.Conclusion The treatment of doxofylline combined with budesonide on the treatment of bronchial asthma had a good effect and more safety,and worthy to be popularized.
引文
[1]安霞,龚颖,叶伶,等.Thl7细胞及其相关细胞因子与支气管哮喘[J].中华哮喘杂志(电子版),2012,6(1):26-29.
[2]杨健楼.多索茶碱与布地奈德联合应用治疗支气管哮喘的临床疗效研究[J].北方药学,2015,12(2):79-80.
[3]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[J].中华结核和呼吸杂志,2008,31(3):177-185.
[4]贺娟梅,李小荣,李复红.支气管哮喘流行病学观察以及危险因素分析[J].山西医科大学学报,2015,46(12):1224-1227.
[5]伦茂春.支气管哮喘的发病机制及临床药物治疗的进展[J].中国医药指南,2014,12(5):63-64.
[6]王勇,应秀娟.小剂量糖皮质激素布地奈德吸入在支气管哮喘治疗中的应用[J].实用药物与临床,2014,17(2):199-200.
[7]孙勇,王利民,银春,等.多索茶碱治疗慢性阻塞性肺疾病168例[J].临床肺科杂志,2013,18(5):924-925.
[8]朴金善.多索茶碱与布地奈德联合治疗支气管哮喘的临床分析[J].中国医药指南,2013,11(2):236-237.
[9]甘兵,钟声,张洪浩,等.白三烯受体拮抗剂对支气管哮喘患者Th1/Th2平衡及肺功能的影响[J].临床肺科杂志,2012,17(4):717-718.
[10]谭磊.多索茶碱与氨茶碱治疗支气管哮喘临床疗效的对比观察[J].当代医学,2012,18(8):11-12.
[11]赵凯姝,张云峰,成焕吉,等,白细胞介素-23、白细胞介素-17在支气管哮喘小鼠发病中的作用[J],实用儿科临床杂志,2010,25(9):639-642.
[2]杨健楼.多索茶碱与布地奈德联合应用治疗支气管哮喘的临床疗效研究[J].北方药学,2015,12(2):79-80.
[3]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[J].中华结核和呼吸杂志,2008,31(3):177-185.
[4]贺娟梅,李小荣,李复红.支气管哮喘流行病学观察以及危险因素分析[J].山西医科大学学报,2015,46(12):1224-1227.
[5]伦茂春.支气管哮喘的发病机制及临床药物治疗的进展[J].中国医药指南,2014,12(5):63-64.
[6]王勇,应秀娟.小剂量糖皮质激素布地奈德吸入在支气管哮喘治疗中的应用[J].实用药物与临床,2014,17(2):199-200.
[7]孙勇,王利民,银春,等.多索茶碱治疗慢性阻塞性肺疾病168例[J].临床肺科杂志,2013,18(5):924-925.
[8]朴金善.多索茶碱与布地奈德联合治疗支气管哮喘的临床分析[J].中国医药指南,2013,11(2):236-237.
[9]甘兵,钟声,张洪浩,等.白三烯受体拮抗剂对支气管哮喘患者Th1/Th2平衡及肺功能的影响[J].临床肺科杂志,2012,17(4):717-718.
[10]谭磊.多索茶碱与氨茶碱治疗支气管哮喘临床疗效的对比观察[J].当代医学,2012,18(8):11-12.
[11]赵凯姝,张云峰,成焕吉,等,白细胞介素-23、白细胞介素-17在支气管哮喘小鼠发病中的作用[J],实用儿科临床杂志,2010,25(9):639-642.